Yamamoto H, Nagata M, Tabe K, Suzuki S, Maruo H, Sakamoto Y, Yamamoto K, Dohi Y
Second Department of Internal Medicine, Saitama Medical School.
Arerugi. 1990 Jan;39(1):21-7.
We examined the inhibitory effect of the long-acting beta-adrenergic agonists, mabuterol, clenbuterol and fenoterol on "morning dipping" in ten patients with nocturnal asthma. On the first night, as a control experiment, the subjects received no beta-adrenergic agonist. On the succeeding three nights at 8:00 PM, each subject was orally administered 50 micrograms of mabuterol, 40 micrograms of clenbuterol and 5 mg of fenoterol in a randomized, crossover fashion. Pulmonary function tests (FVC, FEV1.0, PEFR, V50 and V25) were performed at 8:00 PM (just before administration of beta-adrenergic agonist), 9:00 PM, 10:00 PM, 6:00 AM and 8:00 AM. On the night when clenbuterol was administered, there was a significant inhibition of morning dipping at 6:00 AM in FVC (p less than 0.01), FEV1.0 (p less than 0.01), PEFR (p less than 0.01), V50 (p less than 0.01) and V25 (p less than 0.05) compared with the control night. On the nights when mabuterol and fenoterol were administered, there was a significant inhibition of morning dipping at 6:00 AM in FVC (p less than 0.01) and FEV1.0 (p less than 0.01) compared with the control night. Palpitations associated with clenbuterol administration were seen in two subjects. The effect of each beta-adrenergic agonist varied inconsistently among the subjects. These results indicate that clenbuterol is the most effective in inhibiting morning dipping among the long-acting beta-adrenergic agonists examined, but individualization in the choice of beta-adrenergic agonist is mandatory in order to achieve the maximum effect.
我们研究了长效β-肾上腺素能激动剂马布特罗、克仑特罗和非诺特罗对10例夜间哮喘患者“清晨下降”现象的抑制作用。在第一个晚上,作为对照实验,受试者未接受β-肾上腺素能激动剂。在随后的三个晚上,每晚8点,每位受试者以随机交叉方式口服50微克马布特罗、40微克克仑特罗和5毫克非诺特罗。在晚上8点(恰好在给予β-肾上腺素能激动剂之前)、晚上9点、晚上10点、早上6点和早上8点进行肺功能测试(用力肺活量(FVC)、第一秒用力呼气容积(FEV1.0)、呼气峰流速(PEFR)、50%肺活量时的流速(V50)和25%肺活量时的流速(V25))。在给予克仑特罗的当晚,与对照夜相比,早上6点时FVC(p<0.01)、FEV1.0(p<0.01)、PEFR(p<0.01)、V50(p<0.01)和V25(p<0.05)的清晨下降受到显著抑制。在给予马布特罗和非诺特罗的当晚,与对照夜相比,早上6点时FVC(p<0.01)和FEV1.0(p<0.01)的清晨下降受到显著抑制。两名受试者出现了与克仑特罗给药相关的心悸。每种β-肾上腺素能激动剂的效果在受试者之间变化不一致。这些结果表明,在所研究的长效β-肾上腺素能激动剂中,克仑特罗在抑制清晨下降方面最有效,但为了达到最大效果,必须根据个体情况选择β-肾上腺素能激动剂。